The natural course of aortic stenosis (AS) is generally considered as poor prognosis, and standard treatment of AS is surgical aortic valve replacement (AVR). Transcatheter aortic valve replacement (TAVR) is the treatment that has emerged as minimally invasive treatment for elderly or high-risk AS patients who are generally considered difficult to indicate the surgical AVR. TAVR has become widespread as a new treatment for AS patients along with the evolution of devices, and has been spreading explosively since it was approved in Japan in October 2013. This time, I will introduce the present situation and perspective of TAVR.